Bohui Innovation(300318)

Search documents
博晖创新(300318) - 2024 Q2 - 季度财报
2024-08-29 08:58
Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2024, representing a 15% increase compared to the same period last year[7]. - The company has projected a revenue growth of 10% for the second half of 2024, aiming for a total annual revenue of RMB 1.1 billion[7]. - The company's operating revenue for the reporting period was ¥486.89 million, a decrease of 7.60% compared to the same period last year[12]. - Net profit attributable to shareholders was ¥27.63 million, representing a significant increase of 366.35% year-over-year[12]. - The net profit after deducting non-recurring gains and losses was ¥26.34 million, up 404.11% from the previous year[12]. - The total comprehensive income for the first half of 2024 was CNY 56,026,235.20, compared to CNY 4,545,475.32 in the same period of 2023, marking a substantial improvement[164]. - The company reported a significant increase in investment income, with a total of CNY 927,618.84 in the previous year, indicating a positive trend in investment performance[165]. - The company reported a total comprehensive income increase of approximately 86.5% year-over-year[182]. User Growth and Market Expansion - User data indicates a growth in active users by 20%, reaching a total of 1.2 million users as of June 30, 2024[7]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in sales in that region by the end of 2024[7]. - The company aims to enhance its market presence through the introduction of advanced diagnostic technologies and products[21]. Product Development and Innovation - New product development includes the launch of a microfluidic chip technology, expected to enhance diagnostic capabilities and increase market share[7]. - The company has invested RMB 50 million in R&D for new diagnostic technologies, focusing on molecular diagnostics and HPV detection[7]. - The company continues to develop new products, including a Nucleic Acid Chip Detector for HPV testing, with a registration validity until November 2028[21]. - The company is focused on expanding its product offerings in the field of medical diagnostics, particularly in the detection of trace elements and viral infections[21]. - The company has developed a human trace element detection platform based on atomic absorption and a molecular diagnostic platform based on microfluidic control technology[52]. Financial Management and Investments - The company maintains a strong cash position with RMB 300 million in cash reserves, providing flexibility for future investments[7]. - No cash dividends will be distributed for the current fiscal year, as the company aims to reinvest profits into growth initiatives[2]. - The company has received multiple new patents, including a method for nucleic acid extraction and a hydrogenation reaction device, indicating ongoing innovation[38]. - The company has reported a total investment of CNY 72,342.68 for hazardous waste disposal in Hebei[102]. Regulatory and Compliance - The management has identified potential risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[2]. - The company is committed to adhering to regulatory requirements for innovative medical devices, as indicated by the registration status of its products[20]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, adhering to various environmental standards[63]. Environmental Management - The company has implemented various environmental protection laws and standards in its operations, including the Environmental Protection Law and the Air Pollution Prevention and Control Law[66]. - The company has established a comprehensive quality management system to ensure product safety, complying with national drug production and quality management standards[54]. - The company is committed to maintaining compliance with environmental standards and reducing pollutant emissions[71]. Shareholder and Corporate Governance - The total number of shares outstanding is 816,900,495, with 97.75% being unrestricted shares[144]. - The company has not issued any new shares or conducted any share buybacks during the reporting period[144]. - The company has not reported any changes in the number of restricted shares during the reporting period[144]. - The company has made commitments to avoid conflicts of interest and ensure independent operations, with no violations reported during the reporting period[108]. Risks and Challenges - The company faces risks in medical device product development due to external uncertainties and the complexity of innovation projects[52]. - The company is facing potential risks related to the management of blood plasma collection stations, despite having established a set of management protocols[55]. - The company is currently working on the resumption of production at the Langfang facility, which requires government approval, posing a risk of delays[56]. Future Outlook - Future outlook includes continued innovation in medical technology and expansion of product lines to meet market demands[21]. - The company plans to continue focusing on market expansion and new product development to drive future growth[163].
博晖创新:董事会决议公告
2024-08-29 08:58
北京博晖创新生物技术集团股份有限公司(以下简称"公司"或"博晖创新") 第八届董事会第七次会议于 2024 年 8 月 29 日在公司会议室召开,会议通知于 2024 年 8 月 19 日以专人送达、邮件通知或电话通知的方式送达各位董事,会议 由公司董事长沈治卫先生主持,会议采取现场和通讯表决相结合方式进行,本次 会议应出席董事 7 人,实际出席董事 7 人,监事和高级管理人员列席了会议。本 次会议的召集召开程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 证券代码:300318 证券简称:博晖创新 公告编号:临 2024-027 北京博晖创新生物技术集团股份有限公司 第八届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 本次会议审议通过了以下议案: 1、审议通过《2024 年半年度报告及其摘要》 同意公司根据《深圳证券交易所创业板股票上市规则》、《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》等法律、法规 的相关要求,结合本公司 2024 年上半年的实际经 ...
博晖创新:非经营性资金占用及其他关联资金往来情况汇总表
2024-08-29 08:58
注:①表中非经营性占用部分,关联方范围依照《创业板上市规则》确定。②无控股股东、实际控制人的公司,存在第一大股东或第一大股东关联人非经营性占用资金的,也应填写本表非经营性占用部分。 北京博晖创新生物技术集团股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位:万元 | | | 占用方与上市公 | 上市公司核算 | 2024 年年初占 | 2024 年 1-6 月占 | 2024 年 1-6 | 月 | 2024年1-6月 | 2024 年 6 月末 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 司的关联关系 | 的会计科目 | 用资金余额 | 用累计发生金额 | 占用资金的利 | | 偿还累计发 | 占用资金余额 | 原因 | 占用性质 | | | | | | | (不含利息) | 息(如有) | | 生金额 | | | | | 控股股东、实际控 | | | | | | | | | | | 非经营性占用 | | ...
博晖创新:关于控股子公司下属浆站取得单采血浆许可证的公告
2024-08-13 09:08
证券代码:300318 证券简称:博晖创新 公告编号:临 2024-026 北京博晖创新生物技术集团股份有限公司 关于控股子公司下属浆站取得单采血浆许可证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 近日,北京博晖创新生物技术集团股份有限公司(以下简称"公司")控股子 公司博晖生物制药(河北)有限公司下属彝良博晖单采血浆有限公司(以下简称 "彝良浆站")和永善博晖单采血浆有限公司(以下简称"永善浆站")取得云南省 卫生健康委员会颁发的《单采血浆许可证》,彝良浆站和永善浆站经核准登记, 准予执业。主要信息如下: 一、彝良浆站主要信息 生产单位:博晖生物制药(河北)有限公司; 法定代表人:崔卫东; 机构名称:彝良博晖单采血浆站; 主要负责人:于军; 地址:云南省昭通市彝良县角奎街道塘房社区陈湾小组领秀国际城 7 号; 业务项目:原料血浆采集; 生产单位:博晖生物制药(河北)有限公司; 法定代表人:崔卫东; 机构名称:永善博晖单采血浆站; 主要负责人:张雅琴; 地址:云南省昭通市永善县溪洛渡街道玉泉路 251 号; 业务项目:原料血浆采集; 许可证号:云卫 ...
博晖创新:2023年度股东大会会议决议公告
2024-05-17 10:47
证券代码:300318 证券简称:博晖创新 公告编号:临 2024-025 北京博晖创新生物技术集团股份有限公司 2023 年度股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 特别提示: 1、本次股东大会无否决议案的情况; 2、本次股东大会不涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 北京博晖创新生物技术集团股份有限公司(以下简称"公司")2023 年度股东 大会于 2024 年 5 月 17 日(星期五)下午 14:00 在公司会议室以现场投票和网 络投票相结合的形式召开。通过深圳证券交易所系统进行网络投票的具体时间为: 2024 年 5 月 17 日 9:15—9:25,9:30—11:30 和 13:00—15:00,通过深圳证券交易 所互联网投票的具体时间为:2024 年 5 月 17 日 9:15 至 15:00 期间的任意时间。 会议以现场记名投票表决与网络投票相结合的方式,审议通过了以下议案: 1、审议通过了《2023 年度董事会工作报告》 总表决情况: 本次股东大会由公司董事会召集,董事长沈治卫先生主持,公司 ...
博晖创新:北京国枫律师事务所关于北京博晖创新生物技术集团股份有限公司2023年度股东大会的法律意见书
2024-05-17 10:44
北京国枫律师事务所(以下简称"本所")接受贵公司的委托,指派律师出席并见证 贵公司 2023 年度股东大会(以下简称"本次会议")。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东大会规则》(以下简称 "《股东大会规则》")、《律师事务所从事证券法律业务管理办法》(以下简称"《证券法 律业务管理办法》")、《律师事务所证券法律业务执业规则(试行)》(以下简称"《证券法 律业务执业规则》")等相关法律、行政法规、规章、规范性文件及《北京博晖创新生物 技术集团股份有限公司章程》(以下简称"《公司章程》")的规定,就本次会议的召集与 召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜,出具本 法律意见书。 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话:010-88004488/66090088 传真:010-66090016 邮编:100005 北京国枫律师事务所 关于北京博晖创新生物技术集团股份有限公司 2023 年度股东大会的 法律意见书 国枫律股字[2024]A0260 号 致:北京博晖 ...
博晖创新:关于公司会计政策变更的公告
2024-04-26 08:58
北京博晖创新生物技术集团股份有限公司(以下简称"公司") 根据中华人 民共和国财政部(以下简称"财政部")颁布的《企业会计准则解释第 17 号》(财 会〔2023〕21 号)(以下简称"解释第 17 号")的要求变更公司会计政策。本次 会计政策变更的具体情况如下: 一、会计政策变更情况 (一)会计政策变更原因及变更日期 财政部于 2023 年 10 月 25 日发布了《解释第 17 号》,规定对"关于流动 负债与非流动负债的划分"、"关于供应商融资安排的披露"、"关于售后租回交易 的会计处理"的解释内容,自 2024 年 1 月 1 日起施行。由于上述会计准则解释 的发布,公司需对会计政策进行相应变更,并按以上文件规定的生效日期开始执 行上述会计准则。 (二)变更前采用的会计政策 证券代码:300318 证券简称:博晖创新 公告编号:临 2024-024 北京博晖创新生物技术集团股份有限公司 关于公司会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 二、本次会计政策变更对公司的影响 本次会计政策变更是公司根据财政部相关规定和要求进行的合理变更 ...
博晖创新(300318) - 2024 Q1 - 季度财报
2024-04-26 08:58
Financial Performance - The company's revenue for Q1 2024 was CNY 262,051,377.78, representing a 3.60% increase compared to CNY 252,950,995.14 in the same period last year[5] - Net profit attributable to shareholders was CNY 19,863,584.33, a significant increase of 283.90% from CNY 5,174,206.08 year-on-year[5] - The net profit for Q1 2024 was CNY 42,022,580.71, significantly up from CNY 9,672,620.16 in Q1 2023, marking an increase of 335.5%[28] - Basic and diluted earnings per share were both CNY 0.0243, up 285.71% from CNY 0.0063 in the previous year[5] - The total comprehensive income for the first quarter of 2024 was CNY 41,913,382.88, compared to CNY 9,156,153.67 in the same period last year, representing a significant increase[29] - The net profit attributable to the parent company was CNY 19,754,270.80, up from CNY 4,655,451.57 year-over-year[29] Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 31,910,106.63, marking a 516.83% increase compared to CNY 5,173,217.62 in Q1 2023[5] - Cash flow from operating activities generated a net cash inflow of CNY 31,910,106.63, compared to CNY 5,173,217.62 in the prior year, reflecting a strong operational performance[32] - Total cash inflow from financing activities was CNY 281,668,207.13, down from CNY 693,022,700.66 in the previous year, indicating a decrease in financing activities[33] - The cash and cash equivalents at the end of the period were CNY 69,469,073.15, a decrease from CNY 87,292,850.77 at the end of the previous year[33] - The company reported a cash outflow from investing activities of CNY 72,546,642.65, compared to CNY 65,388,409.04 in the same period last year, indicating increased investment expenditures[32] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 3,984,606,786.57, reflecting a 1.49% increase from CNY 3,926,015,273.52 at the end of the previous year[5] - The total liabilities rose to CNY 1,602,148,374.52, compared to CNY 1,585,470,244.35, an increase of 1.7%[24] - The company’s equity attributable to shareholders increased to CNY 1,389,292,813.18 from CNY 1,369,538,542.38, showing a growth of 1.4%[25] Expenses - Management expenses rose by 33.44% to CNY 40,429,092.55, mainly due to increased material consumption and asset write-offs[10] - The company experienced a 119.27% increase in income tax expenses, totaling CNY 7,808,401.64, driven by growth in revenue and gross profit[10] - Research and development expenses for the quarter were CNY 14,556,648.09, slightly up from CNY 14,197,200.03, indicating a focus on innovation[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 37,809[13] - The largest shareholder, Du Jiangtao, holds 39.03% of shares, totaling 318,811,388 shares[14] - The company has a total of 10 major shareholders, with the top two being spouses, indicating potential related party transactions[14] Investments and Projects - The company approved a total guarantee amount of up to RMB 1.2 billion for subsidiaries, with RMB 400 million specifically for Hebei Bohui[17] - The company signed a cooperation framework agreement to invest RMB 3.3 billion in the "Bohui Biological Modern Pharmaceutical Industry Base" project in Shijiazhuang[19] Inventory and Receivables - Accounts receivable decreased from RMB 53,895,164.57 to RMB 46,551,141.37 during the reporting period[22] - Inventory increased from RMB 854,562,676.21 to RMB 888,169,192.26[22] - The company has signed four receivables guarantee agreements with Zheshang Bank, with a total guarantee amount of RMB 45.496 million[16] Sales Performance - The company’s total revenue from sales of goods and services was CNY 270,726,895.88, compared to CNY 258,419,243.49 in the previous year, showing a growth in sales[31] - The total operating revenue for Q1 2024 was CNY 262,051,377.78, an increase of 3.4% compared to CNY 252,950,995.14 in the same period last year[26] - The total operating costs decreased to CNY 214,677,513.06 from CNY 241,498,331.27, representing a reduction of approximately 11.1%[26] - The company reported a gross profit margin of approximately 18.1% for Q1 2024, compared to 12.5% in the previous year[26]
博晖创新:第八届董事会第六次会议决议公告
2024-04-26 08:58
一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司(以下简称"公司"或"博晖创新") 第八届董事会第六次会议于 2024 年 4 月 26 日在公司会议室召开,会议通知于 2024 年 4 月 15 日以专人送达、邮件通知或电话通知的方式送达各位董事,会议 由公司董事长沈治卫先生主持,会议采取现场和通讯表决相结合方式进行,本次 会议应出席董事 7 人,实际出席董事 7 人,监事列席了会议。本次会议的召集召 开程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 证券代码:300318 证券简称:博晖创新 公告编号:临 2024-020 本次会议审议通过了以下议案: 北京博晖创新生物技术集团股份有限公司 第八届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 表决结果:7 票同意,0 票反对,0 票弃权。同意票数占总票数的 100%。 三、备查文件 1 1、审议通过《2024 年第一季度报告》 同意公司根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所创 业板上市公司第 47 号——上市公司季度报告公告格 ...
博晖创新:第八届监事会第五次会议决议公告
2024-04-26 08:58
证券代码:300318 证券简称:博晖创新 公告编号:临 2024-021 北京博晖创新生物技术集团股份有限公司 第八届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司(以下简称"公司"或"博晖创新")第 八届监事会第五次会议于 2024 年 4 月 26 日在公司会议室召开,会议通知于 2024 年 4月 15日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司监事 会主席杜江虹女士主持,会议采取现场和通讯表决相结合方式进行,本次会议应出 席监事 3 人,实际出席监事 3 人。本次会议的召集召开程序符合《公司法》和《公 司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了以下议案: 1、审议通过《2024 年第一季度报告》 监事会认为:公司结合 2024 年第一季度的实际经营管理情况编制的《2024 年 第一季度报告》符合《深圳证券交易所创业板股票上市规则》、《上市公司信息披露 管理办法》等法律、法规的相关要求。其内容真实、准确、完整的反映了公司 20 ...